Department of Pharmaceutics, Chandigarh College of Pharmacy, Mohali, Punjab, India.
Dr. B.R. Ambedkar Centre for Biomedical Research, University of Delhi, Delhi, India.
Biomed Pharmacother. 2017 Jun;90:906-913. doi: 10.1016/j.biopha.2017.04.042. Epub 2017 Apr 22.
Noscapine (Nos) and reduced brominated analogue of noscapine (Red-Br-Nos) prevent cellular proliferation and induce apoptosis in cancer cells either alone or in combination with other chemotherapeutic drugs. However, owing to poor physicochemical properties, Nos and Red-Br-Nos have demonstrated their anticancer activity at higher and multiple doses. Therefore, in present investigation, silver nanocrystals of noscapinoids (Nos-Ag nanocrystals and Red-Br-Nos-Ag nanocrystals) were customized to augment drug delivery, cytotoxicity, apoptosis and cellular uptake in B16F1 mouse melanoma cancer cells.
Nos-Ag nanocrystals and Red-Br-Nos-Ag nanocrystals were prepared separately by precipitation method. The mean particle size of Nos-Ag nanocrystals was measured to be 25.33±3.52nm, insignificantly (P>0.05) different from 27.43±4.51nm of Red-Br-Nos-Ag nanocrystals. Furthermore, zeta-potential of Nos-Ag nanocrystals was determined to be -25.3±3.11mV significantly (P<0.05) different from -15.2±3.33mV of Red-Br-Nos-Ag nanocrystals. The shape of tailored nanocrystals was slightly spherical and or irregular in shape. The architecture of Nos-Ag nanocrystals and Red-Br-Nos-Ag nanocrystals was crystalline in nature. FT-IR spectroscopy evinced the successful interaction of Ag nanocrystals with Nos and Red-Br-Nos, respectively. The superior therapeutic efficacy of tailored nanocrystals was measured in terms of enhanced cytotoxicity, apoptosis and cellular uptake. The Nos-Ag nanocrystals and Red-Br-Nos-Ag nanocrystals exhibited an IC of 16.6μM and 6.5μM, significantly (P<0.05) lower than 38.5μM of Nos and 10.3μM of Red-Br-Nos, respectively. Finally, cellular morphological alterations in B16F1 cells upon internalization of Nos-Ag nanocrystals and Red-Br-Nos-Ag nanocrystals provided the evidences for accumulation within membrane-bound cytoplasmic vacuoles and in enlarged lysosomes and thus triggered mitochondria mediated apoptosis via caspase activation.
Preliminary investigations substantiated that Nos-Ag nanocrystals and Red-Br-Nos-Ag nanocrystals must be further explored and utilized for the delivery of noscapinoids to melanoma cancer cells.
纳可沙平(Nos)和还原溴代纳可沙平(Red-Br-Nos)可单独或与其他化疗药物联合使用,抑制癌细胞增殖并诱导细胞凋亡。然而,由于其较差的理化性质,Nos 和 Red-Br-Nos 只能在较高剂量和多种剂量下发挥其抗癌活性。因此,在本研究中,纳可沙平类银纳米晶体(Nos-Ag 纳米晶体和 Red-Br-Nos-Ag 纳米晶体)被定制以增强药物递送、细胞毒性、细胞凋亡和 B16F1 小鼠黑色素瘤癌细胞的摄取。
分别通过沉淀法制备 Nos-Ag 纳米晶体和 Red-Br-Nos-Ag 纳米晶体。测量 Nos-Ag 纳米晶体的平均粒径为 25.33±3.52nm,与 Red-Br-Nos-Ag 纳米晶体的 27.43±4.51nm 无显著差异(P>0.05)。此外,Nos-Ag 纳米晶体的 zeta 电位为-25.3±3.11mV,与 Red-Br-Nos-Ag 纳米晶体的-15.2±3.33mV 有显著差异(P<0.05)。定制纳米晶体的形状为轻微的球形或不规则形状。Nos-Ag 纳米晶体和 Red-Br-Nos-Ag 纳米晶体的结构为结晶态。傅里叶变换红外光谱表明,Ag 纳米晶体与 Nos 和 Red-Br-Nos 分别成功相互作用。以增强的细胞毒性、细胞凋亡和细胞摄取来衡量定制纳米晶体的优越治疗效果。与 38.5μM 的 Nos 和 10.3μM 的 Red-Br-Nos 相比,Nos-Ag 纳米晶体和 Red-Br-Nos-Ag 纳米晶体的 IC 分别为 16.6μM 和 6.5μM,有显著差异(P<0.05)。最后,B16F1 细胞摄取 Nos-Ag 纳米晶体和 Red-Br-Nos-Ag 纳米晶体后发生的细胞形态变化提供了证据,表明纳米晶体在细胞膜结合的细胞质空泡内积累,并在增大的溶酶体内积累,从而通过半胱天冬酶激活触发线粒体介导的细胞凋亡。
初步研究证实,Nos-Ag 纳米晶体和 Red-Br-Nos-Ag 纳米晶体必须进一步探索和用于将纳可沙平类递送至黑色素瘤癌细胞。